- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00059995
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma
RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or relapsed lymphoma.
Studienübersicht
Detaillierte Beschreibung
OBJECTIVES:
- Determine the safety and tolerability of MDX-060 monoclonal antibody in patients with refractory or relapsed CD30-positive lymphoma.
- Determine the maximum tolerated dose and dose-limiting toxicity of this drug in these patients.
- Determine the pharmacokinetic profile of this drug in these patients.
- Determine, preliminarily, the efficacy (antilymphoma activity) of this drug in these patients.
OUTLINE: This is an open-label, multicenter, dose-escalation study.
Patients receive MDX-060 monoclonal antibody IV over 90 minutes once weekly for 4 weeks.
Cohorts of 3-6 patients receive escalating doses of MDX-060 monoclonal antibody until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 16 patients are accrued and receive MDX-060 monoclonal antibody at the MTD.
Patients are followed monthly for 3 months and then every 3 months for 18 months or until disease progression.
PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study.
Studientyp
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Cancer Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210-1240
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed B-cell or T-cell lymphoma
- Hodgkin's lymphoma and anaplastic large cell lymphoma eligible
- No HIV-associated lymphoma
CD30-positive disease by biopsy, flow cytometry, or immunohistochemistry
- At least 50% of malignant cells (specifically Reed-Sternberg cells for Hodgkin's lymphoma) must express CD30
Must meet one of the following criteria for relapsed/refractory disease:
Relapsed after prior chemotherapy or radiotherapy and autologous or allogeneic bone marrow transplantation (if appropriate)
- Relapsed disease must be within the prior irradiated field
Disease that is refractory to prior chemotherapy or radiotherapy with no other curative treatment option
- Disease progression must be within the prior irradiated field
- Progressive and evaluable disease (measurable disease required for patients accrued on study after the maximum tolerated dose is determined)
PATIENT CHARACTERISTICS:
Age
- Over 12
Performance status
- ECOG 0-2
Life expectancy
- At least 12 weeks
Hematopoietic
- WBC at least 1,500/mm^3*
- Neutrophil count at least 1,000/mm^3*
- Platelet count at least 75,000/mm^3*
- Hemoglobin at least 8.0 g/dL* NOTE: *Laboratory abnormalities attributable to organ involvement by lymphoma are allowed
Hepatic
- AST no greater than 2 times upper limit of normal (ULN)*
- Bilirubin no greater than 2.0 mg/dL (unless due to Gilbert's syndrome)*
- Hepatitis B surface antigen negative
- Hepatitis C antibody negative NOTE: *Laboratory abnormalities attributable to organ involvement by lymphoma are allowed
Renal
- Creatinine no greater than 2 times ULN* NOTE: *Laboratory abnormalities attributable to organ involvement by lymphoma are allowed
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for 9 months after study participation
- HIV negative
- No other active malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No active significant infection
No apparent opportunistic infection, as indicated by any of the following:
- Purified protein derivative recently determined to be positive
- Infectious infiltrate by chest x-ray
- Recent changes in fever/chill patterns
- New, unexplained neurological symptoms
- No underlying medical condition that would preclude receiving study therapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- No prior anti-CD30 antibody therapy
- No other concurrent biologic therapy
Chemotherapy
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- No concurrent chemotherapy
Endocrine therapy
- No concurrent systemic steroidal therapy (excluding physiologic doses)
Radiotherapy
- See Disease Characteristics
- At least 4 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery
- Not specified
Other
- No other concurrent investigational agents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Maskierung: Keine (Offenes Etikett)
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Steven M. Horwitz, MD, Memorial Sloan Kettering Cancer Center
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- rezidivierendes diffuses großzelliges Lymphom bei Erwachsenen
- rezidivierendes großzelliges Lymphom im Kindesalter
- rezidivierendes Hodgkin-Lymphom bei Erwachsenen
- rezidivierendes/refraktäres Hodgkin-Lymphom im Kindesalter
- rezidivierendes kutanes T-Zell-Non-Hodgkin-Lymphom
- anaplastisches großzelliges Lymphom
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MDX-060-01
- MSKCC-02121
- CDR0000298995 (Registrierungskennung: PDQ (Physician Data Query))
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lymphom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten